A Phase 1/2 interventional study of Losartan in Pulmonary Vein Stenosis and Children, sponsored by The Hospital for Sick Children. Suspended at 1 site in Canada. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2019-07-30.
Sponsored by The Hospital for Sick Children · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis.
It is an open label single arm interventional study. The patient population involves pediatric patients with stenosis in 2 or more pulmonary veins. Patients will be given losartan for 1 year. Outcomes include measures of safety/adverse events and progression of pulmonary vein stenosis.
This pilot study evaluates the safety and feasibility of losartan in pediatric patients with pulmonary vein stenosis.
Large animal studies have demonstrated that losartan can ameliorate the progression of pulmonary vein stenosis in a surgical model of pulmonary vein stenosis.
There is no safety data for losartan in children \< 6months of age or in children with pulmonary vein stenosis. Therefore, this study will test the safety and feasibility of losartan in children in an open label single arm interventional study.
Patient inclusion criteria includes stenosis involving 2 or more pulmonary veins. Patients who are consented into the trial with be on losartan therapy for one year. They will undergo study visits every 3 months. Patients will be screened for adverse events through biochemical tests, routine clinical tests and questionnaires.
An exploratory efficacy analysis will compare progression of pulmonary vein stenosis in children enrolled in losartan to a contemporary cohort of children with pulmonary vein stenosis, who did not receive losartan.
The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 82 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins. Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year.
Drug: Losartan
Losartan is given for 12 months
Also known as: Cozaar
Safety:Number of participants with adverse events
adverse events include hypotension, hyperkalemia, renal dysfunction
Time frame: 12 months
Feasibility:Number of participants eligible and recruited
includes patient recruitment and compliance with protocol
Time frame: 12 months
Progression of pulmonary vein stenosis: survival
Progression of pulmonary vein stenosis measures include survival, morbidity and evidence of progression on clinical tests
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of May 2016, a primary completion of May 2021 and a completion of May 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan
Stenosis, Pulmonary Vein
The Hospital for Sick Children →